The FREND™ COVID-19 total Ab is a point-of-care testing (POCT) which can be used to check whether patient has developed immune response to the nucleocapsid protein of SARS-CoV-2 using human plasma. Forno F10 Cat. COVID19 total Ab, its detection is based on a fluorescent immunoassay showing qualitative result. Accurate result in 3 minutes! With just simple steps of operation, the FREND™ system supports quick decision-making. Laboratory Information System Connectivity In the event of a pandemic, the management of a vast amount of clinical results is important. As many laboratories face challenges in effective arrangement of the essential information( ) , the FREND™ System provides the following advantages: • Automatic Data Transfer & Collect Convenient Data Management Can help monitoring (serosurveillance) Reference (1) Division of Laboratory Systems (DLS), Clinical Laboratory COVID-19

Clinical Performance Evaluation The results of the total 347 clinical samples (219 RT-PCR confirmed positive SARS-CoV-2 and 128 negative/preCOVID-19) are presented in the table below. Interference The interference evaluation test of FREND™ COVID-19 total Ab was conducted according to CLSI Guidelines EP7-A2 using one lot. No interference in the testing of the FREND™ COVID-19 total Ab with 4 interfering substances was observed. Specification Item Assay method Fluorescent immunoassay Sample type EDTA Plasma Sample volume FRENDTM System Storage condition Head Office 12F, 5, Digital-ro 26-gil, Guro-gu,...